Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00794586 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00794586 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 120 participants.
The verdict
NCT00794586, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 2 dose combinations of fosfomycin/tobramycin for inhalation (FTI), following a 28-day course of Aztreonam for Inhalation (AZLI) in patients with cystic fibrosis and Pseudomonas aeruginosa lung infection.
Interventions
- DRUG FTI, AZLI
- DRUG Placebo, AZLI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00794586
The ClinicalTrials.gov registry entry for NCT00794586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FTI, AZLI is the first listed.
NCT00794586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00794586 about?
NCT00794586 is a clinical study titled "Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection". The purpose of this study is to evaluate the safety and efficacy of 2 dose combinations of fosfomycin/tobramycin for inhalation (FTI), following a 28-day course of Aztreonam for Inhalation (AZLI) in patients with cystic fibrosis and Pseudomonas aeruginosa lung infection.
What is the current status of trial NCT00794586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2008-11. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00794586?
The interventions under investigation include: FTI, AZLI (DRUG), Placebo, AZLI (DRUG).
Who is sponsoring clinical trial NCT00794586?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.